Visilizumab
- Generic Name
- Visilizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 219716-33-3
- Unique Ingredient Identifier
- H18SKU3289
- Background
Visilizumab has been investigated for the treatment of Ulcerative Colitis.
- Associated Conditions
- -
- Associated Therapies
- -
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
- Conditions
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2021-12-03
- Target Recruit Count
- 30
- Registration Number
- NCT04722952
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2008-07-23
- Last Posted Date
- 2014-07-18
- Target Recruit Count
- 8
- Registration Number
- NCT00720629
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 38
- Registration Number
- NCT00307827
- Locations
- 🇺🇸
Site Reference ID/Investigator# 71896, Cleveland, Ohio, United States
🇭🇷Site Reference ID/Investigator# 72338, Osijek, Croatia
🇭🇷Site Reference ID/Investigator# 72334, Zagreb, Croatia
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2012-03-12
- Lead Sponsor
- Facet Biotech
- Target Recruit Count
- 25
- Registration Number
- NCT00279435
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2012-03-12
- Lead Sponsor
- Facet Biotech
- Target Recruit Count
- 127
- Registration Number
- NCT00279422
Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease
- Conditions
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2012-03-07
- Lead Sponsor
- Facet Biotech
- Target Recruit Count
- 18
- Registration Number
- NCT00267722
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
🇺🇸Inflammatory Bowel Disease Center, Los Angeles, California, United States
Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease
- Conditions
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2012-03-07
- Lead Sponsor
- Facet Biotech
- Target Recruit Count
- 18
- Registration Number
- NCT00267709
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis
- Conditions
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Facet Biotech
- Target Recruit Count
- 144
- Registration Number
- NCT00267306
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸Inflammatory Bowel Disease Center, Los Angeles, California, United States
Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease
- Conditions
- First Posted Date
- 2002-03-18
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT00032279
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Research Study in Patients With Severe Ulcerative Colitis
- Conditions
- First Posted Date
- 2002-03-18
- Last Posted Date
- 2012-03-07
- Lead Sponsor
- Facet Biotech
- Target Recruit Count
- 20
- Registration Number
- NCT00032305
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.